EQ Stock — Equillium, Inc.

Equillium, Inc. (EQ)

Updated October 16, 2026.

EQ is a Stock. Total return is -91.5% over the past 8 years, 303.3 points behind SPY at 211.8%.

Equillium, Inc. is a clinical-stage biotechnology company developing therapeutics for severe autoimmune and inflammatory disorders, with lead programs including EQ504, an AhR modulator in preclinical development for ulcerative colitis and lung inflammation, and EQ302, a bi-specific inhibitor targeting celiac disease. The company does not currently have an established distribution history. This security may appeal to investors seeking exposure to early-stage biotech development with a focus on immuno-inflammatory disease treatment.

EQ performance versus SPY

Price and return data through 2026-10-16.

Total return is -91.5% over the past 8 years, 303.3 points behind SPY at 211.8%. Over the past year its total return — price change plus distributions reinvested — is -3.2%. Its deepest 1-year drawdown was 62.8%.

EQ key facts

Asset type

Stock

Asset class

Equity

Inception date

10/12/2018

Distribution frequency

None

Last close

$1.19 (as of 2026-10-16)

Market cap

$75,455,618

Average volume

466785.0

Beta

1.918

Payout ratio

0.0%

Forward P/E

1.5314

EPS

$-0.14

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EQ risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 62.8%.

Who may consider EQ — and who may not

It is a weaker fit for investors who need monthly cash flow (EQ does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EQ

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions